(Tiper Stock Exchange) – PharmaNutra closes the 2022 financial year with Revenues from sales consolidated in 2022 amounted to 82.7 million euros, recording a growth of 21.4% compared to the previous year.
The Gross Operating Result of the Group as at 31 December 2022 amounted to 24.4 million Euros (20.1 million in 2021), equal to a margin of 29.2% (unchanged compared to 2021) on total revenues, with a growth of 21, approximately 3% compared to the previous year.
The Net income for the period amounted to Euro 15 million compared to Euro 13.8 million as at 31 December 2021.
There Net Financial Position of 2022 records a reduction of Euro 17.4 million compared to 31 December 2021 due to the investments made and presents a positive balance of Euro 10.6 million compared to Euro 28.1 million in the previous year.
The Board of Directors of the company has resolved to propose to the forthcoming Shareholders’ Meeting, the distribution of a dividend of Euro 0.80 for each entitled share (for a total maximum of Euro 7,714,382) with detachment date of coupon no. 6 on May 8, 2023, payment entitlement date (record date) on May 9, 2023 and dividend payment date on May 10, 2023.